Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-Current Deffered Revenue (2019 - 2025)

Historic Non-Current Deffered Revenue for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $835000.0.

  • 4D Molecular Therapeutics' Non-Current Deffered Revenue fell 3476.56% to $835000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $835000.0, marking a year-over-year decrease of 3476.56%. This contributed to the annual value of $1.1 million for FY2024, which is 874.49% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Non-Current Deffered Revenue of $835000.0 as of Q3 2025, which was down 3476.56% from $219000.0 recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Non-Current Deffered Revenue high stood at $11.7 million for Q1 2021, and its period low was $219000.0 during Q2 2025.
  • Its 5-year average for Non-Current Deffered Revenue is $1.8 million, with a median of $1.1 million in 2023.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Non-Current Deffered Revenue crashed by 8493.58% in 2022 and then soared by 5560.8% in 2024.
  • Over the past 5 years, 4D Molecular Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $2.5 million in 2021, then plummeted by 56.8% to $1.1 million in 2022, then decreased by 9.67% to $972000.0 in 2023, then rose by 8.74% to $1.1 million in 2024, then decreased by 21.0% to $835000.0 in 2025.
  • Its last three reported values are $835000.0 in Q3 2025, $219000.0 for Q2 2025, and $434000.0 during Q1 2025.